Baiyunshan subsidiary secures rabies vaccine registration

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that its subsidiary, Guangzhou Baiyunshan Biological Products Company Limited, received a drug registration certificate from the National Medical Products Administration for its freeze-dried human rabies vaccine (Vero cell). The vaccine is an injectable, with each 0.5ml dose having a rabies vaccine potency of not less than 2.5 IU. This approval, effective until December 21, 2030, classifies the product as a preventive biological product.

The freeze-dried human rabies vaccine (Vero cell) is intended for the prevention of rabies, a severe acute infectious disease transmitted primarily through animal bites. The subsidiary initiated the market registration application on July 19, 2024, which was accepted on July 25, 2024. The company has invested a total of RMB 20,509万元 in research and development for this project.

This registration enriches Guangzhou Baiyunshan Pharmaceutical's product portfolio and is expected to enhance its competitiveness in the vaccine market. However, the company also noted that future sales could be affected by market conditions and other factors inherent to the pharmaceutical industry.